Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Our Chairman knows what he is doing. He identified very early on that the Science at Scancell had multiple potential directions.
You can guess that it was his view that the cash in the bank could only last if the science was reigned in.
Subsequently the decision was made to concentrate on the two Trials. Such things as Modi2 and pursuing an in-house trial on one of our GlyMabs would have to wait for the company to reach cash independence.
This capital raise is doubling down on being totally secure to reach pivitol data points in, I presume, both trials.
There is a possibility that the early trial data ( 2024 ) will be outstanding and a predatory Pharma might make thier move.
Alternatively, we don't know what 2024 will bring, climate, economics, wars and the US election. So ensuring Scancell is well and truly funded is the most pragmatic thing he could do.
So to reach £1 / share, instead of asking for £1B when the data lands early 2025 they now need ask for £1.2B.
Simples.......
Chester.
There were quite a few hints right at the beginning of Botski's recording.
REDMILE, happy with their 29.4% of the company and do not want to take control.
ie: not putting any more funds into Scancell.
GENMAB: Early Milestones not a large amount and all the large cash arrives when they reach phase 3 trials. In around 5 years.
BIG PHARMA: Want a de-risked platform then happy to pay more.
ADDED TOGETHER :
Get the SCOPE trial to the edge of registration and we'll buy the blooming lot.
So this raise is absolutely positive if you believe Immunobody and Moditope work ( the trials say they do ) get your cash out and join in the raise. An over subscribed cash raise tells the wider market to get on board.
Chester.
Hi C11
From what we have been told, the clinical scans that are necessary to build up the data happen at 13 weeks. Noting that the enrolment of the extra 27 patients to the SCOPE trial could have started as early as late September, I'm hopeful that Scancell will hit the required number of responders by February/March.
The Modi1 plus CPi cohort should also reached an important data point around the same time.
As you say, the disclosing RNS'es could land early part of April ( Q2 ). Let's hope that great data arrives on both Trials by then.
Chester.
Thanks Botski really appreciated the chance to listen to whole AGM. Sadly I had to abandon my journey to London at the last minute.
One thing I picked up on, was our Chairman more or less saying that the difficulty with Scancell is the 'Abundance of Richies'.
Since arriving he has brought clarity in the relationship of the platforms / cash needed to achieve important revenue goals. Not trying to cover all bases at once.
Both SCOPE and ModiFY are well poised to produce very valuable data early in 2024.
Chester.
WTP just to add spice to my last post,
"The Successful Transition into the Second Stage" was stated in the RNS dated 19th September.
Two months ago, so we can presume the first of those patients are already recruited and 1st dosed.
We could be well into that number of 27 patients, very exciting times. ( Modi1 + CPI's Next ).
Chester.
WeTookPelham
Let's wait and see how the AGM unfolds.
It's getting awful close to a point where Bristol Myers Squibb are compelled to make Scancell an Offer or broker a deal for a Worldwide Development and Distribution Partnership.
Once this has been achieved :
" The SCOPE trial has now successfully transitioned into the second stage, which will recruit a further 27 patients (for a total of 43). The aim is to achieve at least 18 further responses (i.e., 27 responses in total) which would statistically demonstrate that SCIB1, in combination with doublet therapy, exceeds currently achievable ORRs".
LD will be fending of any Derisory Offers.
Chester.
C11
I totally agree but also want MHRA to only proceed when they are convinced the additional epitopes and the inclusion of AvidiMab are safe.
ISCIB+ is oncology technology that is so new that safety 'belts and braces' are necessary.
As already mentioned, once approval is given it will not take long to enroll the required number of patients. The current Scope Trail is restricted to around 30% of Melanoma suffers. The news of how well SCIB1 + the CPI'S is doing will be known to all the cancer clinicians involved in oncology / Immunology.
If we were ever concerned that we hadn't backed a winner in Scancell, well now we know we have. It's just a matter of time and the positive data will arrived.
Chester.
A genuinely fantastic RNS, not only the increase to 85% but a patient with a clear scan.
In a late stage aggressive desiese these are outstanding outcomes.
If Modi1 plus CPI's match these results there will surely be a bid for the company. There are a half dozen or more Large Pharma Co's that would love to these platforms in-house.
Excellent news for us and cancer patients.
Chester.
From the Reneuron RNS 8th November,
'The Group ended the period to 30 September 2023 with cash, cash equivalents and bank deposits of £5.1 million with the cash runway being extended into the start of calendar Q2 2024.'
No mention of Q125.
Year dates all wrong.
"As of 30 September 2023, Reneuron had cash balance of £5.1m, which we estimate should fund operations into 'Q125', consistent with management's expected cash runway to April 2024" ????
More errors in the Full Report.
Technology making the world dumber.
Only things that have been RNS'd to the market can be discussed at the AGM. What can be projected either via the presentation or the Q&A section, is how things are progressing especially the Trials and potential discussions becoming Deals.
There is time yet to have an RNS land.
For instance, it would be nice to hear if iSCIB+ is close to approval.
Chester.
Hi Phil
From : PharmaWeb.com
'What is the market for exosome diagnostics and therapeutics?'
According to the report, the global exosome diagnostic and therapeutic industry was estimated at $224.34 million in 2020, and is anticipated to hit $2.9 billion by 2030, registering a CAGR of 29.4% from 2021 to 2030.
So it shows that there is definitely a growing market for a Fully Working Exosome Platform.
Chester.
The attraction of this share is the potential upside if any positive news does land.
What we do know is that Exosomes have the potential to improve the targeted delivery of some drugs that lack the precision to find their designated human cells.
We also know that some fairly sizeable deals have already been made and Exosomes that achieve their potential will be worth £10M's.
Reneuron may have just proved that their Exosomes are some of the best in class.
Obviously proved in their own labs but interested parties must be examining the data.
My opinion is that they have better than a 50/50 chance to do a deal before next February/ March.
Added to these assumptions is that the market Capitalisation is so low that the Assets, Patents and Intellectual Property are probably worth much more.
Chester18.
"Inflamed Adrenal Glands" near to the kidneys, does not sound like a Immunobody side affect. I may be wrong but I don't think SCIB1 causes that kind of off-target toxicity.
Also, there is no mention of CPI's so it cannot be that part of our trial.
Only my opinion from what we have been told in the past.
Chester.
That is a chunky purchase and goes directly against the current sentiment of selling off RENE.
It is such a large and positive statement that I'm wondering if we'll see more of the same tomorrow.
Chester.
Subject: Re: SCIB1 Charts September/ November
To Burble et al:
Answer from Scancell regarding the difference in the two Swimmer Line Charts as presented as Abstracts at a conference in September and the one presented on the 9th November.
"We have two cohorts in the SCOPE study one is SCIB1 with @CTLA4 and @PD1 and this is the cohort that have an 82% response rate and are doing amazingly well. The second cohort is SCIB1 with just @PD1. This cohort has a 67% response rate but is difficult to recruit too as most patients get the double checkpoints. We only have three patients in this cohort. The poster reflects both groups and the abstracts are submitted well before the meetings. The SMR meeting was a late breaking session so the abstracts were submitted nearer the meeting although the meeting was after the CIMT meeting. So the simple answer is timing and cohorts but the bottom line is the double checkpoint group plus SCIB1 is doing very well".
kind regards,
Prof Lindy Durrant
CEO
Chester.